DNA Methylation Explained: Mechanism, CpG Islands & Enzymes

DNA methylation involves adding methyl groups to cytosine bases at CG/GC sites via DNA methyltransferases. During early development, methyl groups are erased, then re-established during differentiation to silence or activate specific genes. Maintenance methyltransferase Dnmt1 preserves these patterns during cell division by targeting hemimethylated DNA. Histone modifications (acetylation, phosphorylation, methylation) alter chromatin packing and gene accessibility. Acetylation decreases packing, promoting transcription, while methylation effects vary by residue. These modifications function individually or combinatorially to regulate transcription, replication, DNA repair, and apoptosis. Different modifications create distinct peak profiles detectable in ChIP-seq data, enabling genome-wide mapping of regulatory elements.

Histones have N-terminal tails that extend beyond the nucleosome core and can be chemically modified. Approximately 600 different histone modifications have been identified, including methylation, acetylation, phosphorylation, and ubiquitination. These modifications alter histone conformation and affect DNA accessibility. Histone acetylation neutralizes positive charges on histones, reducing their affinity for negatively charged DNA and making chromatin more accessible for transcription. DNA methylation at CpG sites is associated with transcriptional repression and is reversible. Together with histone modifications, DNA methylation forms part of the epigenetic machinery that regulates gene expression profiles in different tissues and cell types.

Epigenetics refers to external modifications to DNA that turn genes on or off without changing the DNA sequence itself, primarily through two mechanisms: DNA methylation (the addition of a methyl group to DNA that prevents certain genes from being expressed) and histone modification (chemical changes to histone proteins that alter how tightly DNA wraps around them, thereby controlling gene accessibility); these epigenetic processes are influenced by various factors including development, environmental chemicals, diet, and drugs, and can contribute to diseases such as cancer, autoimmune disorders, mental disorders, and diabetes.

Histone acetylation and methylation are key epigenetic mechanisms that regulate gene expression by modifying chromatin structure; acetylation, catalyzed by histone acetyltransferase (HAT), adds acetyl groups to lysine residues on histone tails, neutralizing their positive charge and reducing DNA-histone interactions to allow DNA unwrapping and transcription, while deacetylation by histone deacetylase (HDAC) reverses this process; methylation, catalyzed by histone methyltransferase, can either activate or repress genes depending on the specific lysine or arginine residue modified and the cellular context, as demonstrated by X-chromosome inactivation where trimethylation of H3K9 silences entire chromosomes.

DNA methylation works in concert with histone modifications to regulate gene expression through interconnected mechanisms. Methyl-CpG binding domain proteins recruit histone methyltransferases or deacetylases to promoters, creating a positive feedback loop where DNA methylation reinforces chromatin compaction and transcriptional repression. This integration explains how the same genomic region can be transcriptionally active or silent depending on the balance between activating and repressive modifications. The concept of the epigenetic code encompasses both DNA methylation and histone modifications as heritable layers of gene regulation. While all cells share the same genetic code, different cell types possess distinct epigenetic codes determining gene expression profiles. This explains how the same genome produces diverse cell types—from liver cells to brain cells—through differential epigenetic programming, challenging traditional views of genetic determinism.

Abnormal DNA methylation can cause cancer: hypermethylation of tumor suppressor genes silences them (preventing cell cycle control); hypomethylation of oncogenes can permanently activate them. Environmental factors like diet, stress, and chemicals can cause these epigenetic changes, demonstrating how environment influences gene expression without changing DNA sequence.

Aberrant DNA methylation drives cancer development through two mechanisms: hypermethylation silences tumor suppressor genes (removing cellular brakes) and hypomethylation activates oncogenes (accelerating cell division). DNA methylation inhibitors like 5-azacytidine restore tumor suppressor expression in cancer cells. ICF syndrome demonstrates methylation's essential role in health—mutations in DNMT3B cause immunodeficiency, centromere instability, and facial anomalies. These examples illustrate how proper methylation patterns are critical for normal cellular function and that disrupting these patterns leads to disease, establishing DNA methylation as a therapeutic target in medicine.

Aberrant DNA methylation patterns are implicated in numerous human diseases including cancer (hypermethylation of tumor suppressor genes like p53 and p16), neurological disorders, cardiovascular diseases involving TNF-alpha regulation, and autoimmune conditions. Understanding these methylation patterns provides potential therapeutic targets and diagnostic biomarkers. The field faces challenges including distinguishing causal from correlative methylation changes and accounting for environmental influences on methylation patterns throughout an individual's lifespan.

Tumour suppressor genes inhibit cell division and prevent cells with damaged DNA from forming tumours; when these genes become inactivated through mutations (such as BRCA1/BRCA2 or TP53/p53), or when their promoters undergo hypermethylation (silencing the gene), cells can divide uncontrollably and form tumours. Conversely, hypomethylation of oncogenes increases their expression, promoting excessive cell division and cancer development.

Epigenetic editing represents a new therapeutic modality that takes advantage of gene editing technology but instead of cutting or nicking DNA, it uses targeting domains fused to epigenetic modification domains (like DNA methyltransferases or histone modifiers) to alter the epigenetic state of specific genomic regions. This technology has applications in cancer therapy (rewiring immune cells to be more efficacious against tumors) and other diseases. The lead program at Tune Therapeutics targets hepatitis B, where the therapy uses an mRNA-encoded epigenetic editor and guide RNA that targets the regulatory region of the hepatitis B genome, methylating the site and compacting chromatin to shut down viral expression. This approach offers a potential functional cure for hepatitis B, which is the largest driver of liver cancer globally with over 250 million patients worldwide.

Traditional CRISPR-Cas9 cuts DNA permanently, but dead Cas9 (dCas9) can bind specific sequences without cutting. Fused to epigenetic enzymes like TET1 (removes methyl tags) or DNMT3A (adds methyl tags), dCas9 creates programmable dimmer switches. This allows targeted activation or silencing of specific genes without permanent genetic changes. Applications include telomere rejuvenation by reactivating the TERT gene in T cells, extending replicative lifespan without permanent genetic alterations.

Wild-type Cas9 performs genome editing while dead Cas9 (dCas9) enables epigenetic editing through chemical modifications to DNA or histone proteins that influence chromatin organization and gene expression. Various epigenetic modifying enzymes including histone demethylases (HDM), methyltransferases (HMT), acetyltransferases (HAT), and DNA methyltransferases (DNMT) can be fused with dCas9 to control diverse epigenetic states. Conventional chromatin imaging tools are limited to fixed cells, but dCas9-mediated imaging allows visualization of chromatin in live cells, enabling study of temporal and spatial genome behavior. Single guide RNA-dependent EGFP fused to dCas9 can dynamically image repetitive elements in telomeres and coding genes.

Scientists have developed systems for editing the epigenome that are considered 'better than CRISPR' because they can make changes without altering the DNA sequence itself. These systems use enzymes like methyltransferases to add or remove methyl groups at specific locations. This allows for precise control over gene expression without permanently changing the genetic code, offering potential therapeutic applications for diseases caused by abnormal gene expression.

CRISPRoff is a novel CRISPR-based tool that enables reversible epigenetic gene silencing through a single fusion protein containing dead Cas9 (dCas9), KRAB domains for transcriptional repression, and DNA methyltransferases (DNMT3a/3L) to add methyl groups to DNA, creating heritable epigenetic marks that persist through cell divisions and differentiation for up to 15 months, while its antagonist CRISPRon can reverse these modifications; this technology offers a safer alternative to traditional CRISPR-Cas9 by avoiding double-stranded DNA breaks while providing precise, reversible control over gene expression.